ZVSA Research | Milton Maxwell

ZVSA

ZyVersa Therapeutics, Inc.

0.1330

-0.0020-1.48%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

1.08M

P/E (TTM)

Basic EPS (TTM)

-3.32

Dividend Yield

Recent Filings

8-K

ZyVersa raises $1M via notes

3/5/26Mar 5, 2026

ZyVersa Therapeutics closed a $1 million private placement of convertible notes at 10% interest maturing in 12 months, plus Series A-4 warrants exercisable after six months. Notes convert at 80% of a qualified offering price or recent VWAP with $0.02 floor; proceeds fund working capital. Subsidiary guarantees obligations.

8-K

Director Finizio resigns immediately

12/3/25Dec 3, 2025

ZyVersa Therapeutics' independent director Robert G. Finizio resigned from the Board, Compensation Committee chair, and Audit Committee on December 2, 2025, effective immediately, citing personal reasons. No disagreements with company operations, policies, or practices. Board accepted promptly.

8-K

Q3 loss balloons on R&D impairment

11/19/25Nov 19, 2025

ZyVersa Therapeutics reported Q3 2025 net loss of $19.8 million, up from $2.4 million last year, driven by $18.6 million R&D impairment from market cap decline and financing doubts. Cash stood at $0.5 million, funding operations month-to-month only. R&D expenses fell 16.3% to $0.4 million. Additional financing is essential.

10-Q

Q3 FY2025 results

11/19/25Nov 19, 2025

ZyVersa posted a Q3 net loss of $19.8M, up sharply from $2.4M y/y due to a one-time $18.6M IPR&D impairment from sustained market cap decline, while core R&D fell 16% to $0.4M and G&A dipped 5% to $1.7M on lower insurance and professional fees. Cash burned $4.7M YTD (vs $6.3M y/y), ending at $0.5M after $3.7M warrant raises, leaving a $11.8M working capital deficit. No revenue yet; EPS fell to $(2.56) on 7.7M shares, anti-dilution from 7.3M warrants excluded. Cash lasts month-to-month. Nasdaq delisting crimps liquidity.

8-K

CMO Guzman resigns abruptly

10/15/25Oct 15, 2025

ZyVersa Therapeutics' Chief Medical Officer and Senior Vice President of Medical Affairs, Pablo Guzman, M.D., resigned on October 10, 2025, after joining in January 2015 with over 35 years in interventional cardiology. He steps down to focus on family and travel. No successor named yet. This leadership shift could disrupt clinical pipeline momentum.

About

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.

CEO

Mr. Stephen C. Glover

IPO

2/11/2022

Website

https://www.zyversa.com

Employees

Sector

Healthcare

Industry

Biotechnology